Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
Tetsuya ShindoTakeshi MaehanaToshiaki TanakaKohei HashimotoKo KobayashiAtsushi TakahashiHiroshi HottaYasuharu KunishimaKeisuke TaguchiHitoshi TachikiNaoki ItoMasanori MatsukawaRyuichi KatoShintaro MiyamotoShiro HinotsuNaoya MasumoriPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
Considering the similarity of these risk factors in two sequential treatments, it may be possible to predict the response to pembrolizumab according to the response to prior chemotherapy.